Therapeutic area
Neuroscience biotech companies
The 12 neuroscience companies we cover, with cash and runway from their latest SEC filings, trial milestones from ClinicalTrials.gov, and FDA decisions from their own 8-Ks. Companies are tagged by the areas their pipelines target.
Companies
| Company | Most advanced program | Cash & investments | Runway | Profile |
|---|---|---|---|---|
| VRTXVertex Pharmaceuticals | Trikafta · cystic fibrosisApproved | $13.64B2026-06-30 | — | maintained |
| IONSIonis Pharmaceuticals | Tryngolza · familial chylomicronemia syndromeApproved | $2.70B2026-06-30 | ~71 mo | archived |
| PRAXPraxis Precision Medicines | PRAX-562 · Developmental and epileptic encephalopathies (DEEs), including SCN2A and SCN8A-related epilepsyPhase 2 | $1.37B2026-06-30 | ~50 mo | maintained |
| NBIXNeurocrine Biosciences | Valbenazine · Chorea Associated with Huntington DiseaseApproved | $482M2026-06-30 | — | archived |
| ABBVAbbVie | Skyrizi · psoriasis, inflammatory bowel disease, and related immunology usesApproved | no filing parsed | — | archived |
| ACADACADIA Pharmaceuticals | Nuplazid · Parkinson disease psychosisApproved | no filing parsed | — | archived |
| ARGXargenx SE | Vyvgart · Generalized Myasthenia GravisApproved | no filing parsed | — | archived |
| BIIBBiogen | Leqembi · Alzheimer diseaseApproved | no filing parsed | — | archived |
| DNLIDenali Therapeutics | DNL310 · Hunter syndromePhase 2 | no filing parsed | — | archived |
| MNMDMindMed | MM120 (lysergide D-tartrate ODT) · Generalized anxiety disorder (GAD)Phase 3 | no filing parsed | — | ticker changed |
| PRTAProthena | Birtamimab · AL amyloidosisPhase 3 · stopped | no filing parsed | — | archived |
| SAVACassava Sciences | Simufilam · Alzheimer diseasePhase 3 · stopped | no filing parsed | — | archived |
Runway is cash divided by quarterly operating burn and is not shown for companies funded by their own revenue. Figures and their dates are on each company page, linked to the filing.
Upcoming trial milestones
- 2026-12 · IONS · Donidalorsen OLE: Donidalorsen in Hereditary angioedema prophylaxis — primary completion ClinicalTrials.gov
- 2027-01-25 · VRTX · Suzetrigine DPN open-label extension: Suzetrigine in Diabetic peripheral neuropathic pain — primary completion ClinicalTrials.gov
- 2027-03 · DNLI · BIIB122 LRRK2-PD: BIIB122 in LRRK2-associated Parkinson disease — primary completion ClinicalTrials.gov
- 2027-04-06 · VRTX · ELX/TEZ/IVA non-F508del: Elexacaftor/tezacaftor/ivacaftor in Cystic fibrosis, non-F508del genotypes — primary completion ClinicalTrials.gov
- 2027-05-31 · VRTX · Suzetrigine DPN Phase 3: Suzetrigine in Pain associated with diabetic peripheral neuropathy — primary completion ClinicalTrials.gov
- 2027-08 · ACAD · ACP-211 MDD: ACP-211 in Major depressive disorder with inadequate response — primary completion ClinicalTrials.gov
- 2027-12 · DNLI · COMPASS: Tividenofusp alfa in Mucopolysaccharidosis type II (Hunter syndrome) — primary completion ClinicalTrials.gov
- 2028-01 · ACAD · ADVANCE-2 master protocol: ACP-204 in Alzheimer's disease psychosis — primary completion ClinicalTrials.gov
- 2028-03 · ABBV · Venetoclax ramp-up CLL: Venetoclax in Previously untreated chronic lymphocytic leukaemia — primary completion ClinicalTrials.gov
- 2028-06-23 · BIIB · Salanersen SMA 15-60y: Salanersen (BIIB115) in Spinal muscular atrophy, ages 15-60 — primary completion ClinicalTrials.gov
- 2028-08 · DNLI · DNL126: DNL126 in Mucopolysaccharidosis type IIIA (Sanfilippo A) — primary completion ClinicalTrials.gov
- 2028-11-28 · BIIB · Salanersen presymptomatic infants: Salanersen (BIIB115) in Presymptomatic spinal muscular atrophy — primary completion ClinicalTrials.gov
- 2029-06 · IONS · Donidalorsen paediatric: Donidalorsen in Hereditary angioedema, ages 2 to <12 — primary completion ClinicalTrials.gov
- 2029-07-27 · BIIB · Salanersen post-onasemnogene: Salanersen (BIIB115) in SMA after onasemnogene abeparvovec — primary completion ClinicalTrials.gov
- 2030-08 · IONS · Olezarsen paediatric FCS: Olezarsen in Familial chylomicronemia syndrome — primary completion ClinicalTrials.gov
A registry milestone is the date data collection is scheduled to end, not the date results are released.
FDA decisions
None of these companies has an FDA decision on our PDUFA calendar, which lists only dates a company has stated in a filing.
Educational information, not investment advice. See where each field comes from.